

Role of MSC-derived galectin 3 in the AML microenvironment

Peter P. Ruvolo, Vivian R. Ruvolo, Jared K. Burks, YiHua Qiu, Rui-Yu Wang, Elizabeth J. Shpall, Leonardo Mirandola, Numsen Hail, Jr, Zhihong Zeng, Teresa McQueen, Naval Daver, Sean M. Post, Maurizio Chiriva-Internati, Steven M. Kornblau, Michael Andreeff

PII: S0167-4889(18)30062-4
DOI: doi:10.1016/j.bbamcr.2018.04.005
Reference: BBAMCR 18267

To appear in:

Received date: 28 November 2017
Revised date: 9 April 2018
Accepted date: 10 April 2018

Please cite this article as: Peter P. Ruvolo, Vivian R. Ruvolo, Jared K. Burks, YiHua Qiu, Rui-Yu Wang, Elizabeth J. Shpall, Leonardo Mirandola, Numsen Hail, Jr, Zhihong Zeng, Teresa McQueen, Naval Daver, Sean M. Post, Maurizio Chiriva-Internati, Steven M. Kornblau, Michael Andreeff , Role of MSC-derived galectin 3 in the AML microenvironment. The address for the corresponding author was captured as affiliation for all authors. Please check if appropriate. Bbamcr(2018), doi:10.1016/j.bbamcr.2018.04.005

Role of MSC-derived Galectin 3 in the AML Microenvironment

Peter P. Ruvolo[1,2], Vivian R. Ruvolo[1,2], Jared K. Burks[1,2], YiHua Qiu[1,2], Rui-Yu Wang[1,2], Elizabeth J. Shpall[3], Leonardo Mirandola[4], Numsen Hail, Jr. [1,2], Zhihong Zeng[1,2], Teresa McQueen[1,2], Naval Daver[1], Sean M. Post[1], Maurizio Chiriva-Internati[4,5], Steven M. Kornblau[1,2*] and Michael Andreeff[1,2*]

From the [1]Department of Leukemia, [2]Section of Molecular Hematology, University of Texas MD Anderson Cancer Center, Houston, TX; [3]Department of Stem Cell Transplantation, University of Texas MD Anderson Cancer Center, Houston, TX; [4]Kiromic Biopharma, Houston, TX; [5]Department of Lymphoma and Myeloma, University of Texas MD Anderson Cancer Center, Houston, TX

* These authors contributed equally to the manuscript.

Corresponding Author: Peter Ruvolo, Department of Leukemia, The University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030. E-mail: pruvolo@mdanderson.org